tiprankstipranks
Recursion Pharmaceuticals Reports Q3 2024 Earnings and Strategic Milestones
PremiumCompany AnnouncementsRecursion Pharmaceuticals Reports Q3 2024 Earnings and Strategic Milestones
14d ago
Closing Bell Movers: AppLoving up 29% after Q3 earnings beat
Premium
The Fly
Closing Bell Movers: AppLoving up 29% after Q3 earnings beat
14d ago
Recursion Pharmaceuticals reports Q3 EPS (34c), consensus (35c)
Premium
The Fly
Recursion Pharmaceuticals reports Q3 EPS (34c), consensus (35c)
14d ago
Recursion Pharmaceuticals call volume above normal and directionally bullish
PremiumThe FlyRecursion Pharmaceuticals call volume above normal and directionally bullish
28d ago
Recursion Pharmaceuticals doses first patient in Phase 2 trial of REC-3964
Premium
The Fly
Recursion Pharmaceuticals doses first patient in Phase 2 trial of REC-3964
29d ago
Cathie Wood’s ARK Investment buys 425K shares of Recursion Pharmaceuticals today
Premium
The Fly
Cathie Wood’s ARK Investment buys 425K shares of Recursion Pharmaceuticals today
1M ago
Cathie Wood’s ARK Investment bought 412K shares of Recursion Pharmaceuticals
PremiumThe FlyCathie Wood’s ARK Investment bought 412K shares of Recursion Pharmaceuticals
3M ago
ESPN goes dark on DirecTV, Harris to oppose Nippon-U.S. Steel deal: Morning Buzz
Premium
The Fly
ESPN goes dark on DirecTV, Harris to oppose Nippon-U.S. Steel deal: Morning Buzz
3M ago
Recursion Pharmaceuticals price target lowered to $6 from $8 at Jefferies
Premium
The Fly
Recursion Pharmaceuticals price target lowered to $6 from $8 at Jefferies
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100